Japanese Foundation for Cancer Research collaborates with Takeda Pharma

Japanese Foundation for Cancer Research (JFCR) and Takeda Pharmaceutical have signed a partnership agreement with the goal to advance research and development in the field of oncology.

Under the terms of this agreement, JFCR and Takeda will engage in mutual exchange utilising each other's strengths for the purpose of advancing global early clinical trials and facilitating translational research based on this agreement. This will include active information exchanging and consultation regarding ongoing drug development.

The partnership seeks to expedite the development of groundbreaking anti-cancer therapies and facilitate their swift delivery to cancer patients and their families.

Regarding this development partnership, Toshio Asano, Chairman of JFCR, stated, "We are confident that by joining forces with Takeda, which has outstanding drug discovery and development capabilities worldwide, and JFCR, which has a unique organization integrating hospital and research divisions, we will come closer to our mission of 'conquering cancer'."

“We are thrilled to be collaborating with JFCR,” said Phuong Khanh (P.K.) Morrow, Head of the Oncology Therapeutic Area Unit at Takeda. “This is an exciting opportunity to synergise JFCR's expertise in clinical research with Takeda's clinical development capabilities to advance the development of new potential therapies.”